<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02175342</url>
  </required_header>
  <id_info>
    <org_study_id>205.127</org_study_id>
    <nct_id>NCT02175342</nct_id>
  </id_info>
  <brief_title>Pharmacodynamic and Pharmacokinetic Dose Ranging Study of Tiotropium Bromide Administered Via Respimat Device in Patients With Chronic Obstructive Pulmonary Disease (COPD)</brief_title>
  <official_title>Pharmacodynamic and Pharmacokinetic Dose Ranging Study of Tiotropium Bromide Administered Via Respimat Device in Patients With Chronic Obstructive Pulmonary Disease (COPD): a Randomized, 3-week Multiple-dose, Placebo Controlled, Intraformulation Double-blind, Parallel Group Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      This pharmacodynamic and pharmacokinetic dose-ranging study aims to determine the optimal
      dose of tiotropium inhaled as a solution from a Respimat device once a day for three weeks in
      patients with COPD.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 1998</start_date>
  <primary_completion_date type="Actual">April 1999</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Forced expiratory volume in one second (FEV1) with emphasis on the last two hours of the 24-hour dosing interval (trough FEV1)</measure>
    <time_frame>last two hours of the 24-hour dosing interval</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Forced expiratory volume in one second (FEV1)</measure>
    <time_frame>during the first four hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced Vital Capacity (FVC)</measure>
    <time_frame>during first four hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic evaluation: 2-hours urine sampling pre- and post-dose (10 patients per group)</measure>
    <time_frame>before and after last drug administration at day7,14 and 21.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chronic obstructive pulmonary disease symptom scores, physician's global evaluation, sleep question and use of rescue medication</measure>
    <time_frame>3 weeks treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in ECG, pulse rate (PR) and blood pressure (BP) from the pre-dose values recorded on test day</measure>
    <time_frame>Day 0, day 7, day 14, day 21</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in ECG, physical examination, haematology and biochemistry recorded before and after the trial</measure>
    <time_frame>Screening, 24 to 28 days after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of adverse events</measure>
    <time_frame>up to 28 days</time_frame>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">202</enrollment>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <arm_group>
    <arm_group_label>Tiotropium-1.25 Respimat</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two puffs of tiotropium inhalation solution from a Respimat device, 0.625 mcg/puff</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tiotropium-2.5 Respimat</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two puffs of tiotropium inhalation solution from a Respimat device, 1.25 mcg/puff</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tiotropium-5 Respimat</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two puffs of tiotropium inhalation solution from a Respimat device, 2.5 mcg/puff</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tiotropium-10 Respimat</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two puffs of tiotropium inhalation solution from a Respimat device, 5 mcg/puff</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tiotropium-20 Respimat</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two puffs of tiotropium inhalation solution from a Respimat device, 10 mcg/puff</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Respimat</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Tiotropium-18 lactose powder Handihaler</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo lactose powder Handihaler</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tiotropium 0.625 mcg/puff</intervention_name>
    <arm_group_label>Tiotropium-1.25 Respimat</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tiotropium 1.25 mcg/puff</intervention_name>
    <arm_group_label>Tiotropium-2.5 Respimat</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tiotropium 2.5 mcg/puff</intervention_name>
    <arm_group_label>Tiotropium-5 Respimat</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tiotropium 5 mcg/puff</intervention_name>
    <arm_group_label>Tiotropium-10 Respimat</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo solution</intervention_name>
    <arm_group_label>Placebo Respimat</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tiotropium-18 lactose powder</intervention_name>
    <arm_group_label>Tiotropium-18 lactose powder Handihaler</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo lactose powder</intervention_name>
    <arm_group_label>Placebo lactose powder Handihaler</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tiotropium 10 mcg/puff</intervention_name>
    <arm_group_label>Tiotropium-20 Respimat</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Respimat</intervention_name>
    <arm_group_label>Tiotropium-1.25 Respimat</arm_group_label>
    <arm_group_label>Tiotropium-2.5 Respimat</arm_group_label>
    <arm_group_label>Tiotropium-5 Respimat</arm_group_label>
    <arm_group_label>Tiotropium-10 Respimat</arm_group_label>
    <arm_group_label>Tiotropium-20 Respimat</arm_group_label>
    <arm_group_label>Placebo Respimat</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Handihaler</intervention_name>
    <arm_group_label>Tiotropium-18 lactose powder Handihaler</arm_group_label>
    <arm_group_label>Placebo lactose powder Handihaler</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age: ≥ 40 years;

          2. Diagnosis of COPD and met the following criteria:

               1. Relatively stable, moderate to severe airway obstruction,

               2. Baseline 30% ≤ FEV1 ≤ 65% of predicted normal value, predicted normal values are
                  based on the guidelines for standardized lung function testing of the European
                  Community for Coal and Steel (ECCS) ,

               3. Baseline FEV1/ forced expiratory vital capacity (FEVC) ≤ 70%;

          3. Smoking history ≥ 10 pack-years (p.y.). A p.y. is defined as the equivalent of smoking
             one pack of cigarettes per day for one year;

          4. Male of female;

          5. Ability to be trained in the proper use of Respimat and Handihaler;

          6. Ability to be trained in the performance of technically satisfactory pulmonary
             function tests;

          7. Ability to provide written informed consent

          8. Patient affiliated to the Social Security System

        Exclusion Criteria:

          1. History of asthma, allergic rhinitis or atopy or who have a blood eosinophil count
             above 600/mm³

          2. Changes in the therapeutic (pulmonary) plan within the last six weeks prior to the
             Screening Visit;

          3. Treatment by cromolyn/nedocromil sodium;

          4. Treatment by antihistamines (H1 receptor antagonists);

          5. A lower respiratory tract infection or any exacerbation in the past six weeks prior to
             the Screening Visit;

          6. Regular use of daytime oxygen therapy;

          7. Treatment by oral corticosteroid medication if initiated or modified within the last
             six weeks or if daily dose &gt; 10 mg prednisone equivalent;

          8. History of life threatening pulmonary obstruction, cystic fibrosis or bronchiectasis

          9. Patients who have undergone thoracotomy with pulmonary resection;

         10. History of clinically significant cardiovascular, renal neurologic, liver or endocrine
             dysfunction. A clinically significant disease was defined as one which in the opinion
             of the investigator may either put the patient at risk because of participation in the
             study or a disease which may influence the results of the study or the patient's
             ability to participate in the study.

         11. Patients with a recent (≤ one year) history of myocardial infarction, of heart failure
             or patients with any cardiac arrhythmia requiring drug therapy;

         12. Tuberculosis with indication for treatment;

         13. History of cancer within the last five years. Patients with treated basal cell
             carcinoma were allowed:

         14. Current psychiatric disorders;

         15. Patients with known symptomatic prostatic hypertrophy or bladder neck obstruction;

         16. Patients with any history of glaucoma or increased intra-ocular pressure;

         17. Patients with clinically significant abnormal baseline haematology or blood chemistry,
             if the abnormality defines a disease listed as an exclusion criterion;

         18. Patients with

               1. glutamyl-oxalo-acetic transaminase/glutamyl-pyruvic transaminase (SGOT/SGPT): &gt;
                  200% of the upper limit of the normal range (ULN, )

               2. bilirubin: &gt; 150% of the ULN,

               3. creatinine: &gt; 125% of the ULN;

         19. Intolerance to aerosolised anticholinergic containing products, and/or
             hypersensitivity to benzalkonium chloride, to lactose or any other components of the
             inhalation capsule delivery system;

         20. Beta-blocker medication;

         21. Concomitant or recent (within the last month) use of investigational drugs;

         22. History of drug abuse and/or alcoholism;

         23. Pregnant or nursing women and women of childbearing potential not using a medically
             approved means of contraception ( urinary pregnancy test at screening);

         24. Previous participation in this study (i.e. having been allocated a randomised
             treatment number);

         25. Patients deprived of their freedom by a judicial or administrative decision;

         26. Minors, adults under guardianship;

         27. Persons in medical or social establishments;

         28. Patients in emergency situations
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 24, 2014</study_first_submitted>
  <study_first_submitted_qc>June 25, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 26, 2014</study_first_posted>
  <last_update_submitted>June 25, 2014</last_update_submitted>
  <last_update_submitted_qc>June 25, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 26, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Chronic Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Tiotropium Bromide</mesh_term>
    <mesh_term>Bromides</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

